๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Tianeptine versus fluoxetine in the treatment of depression complicating Alzheimer's disease

โœ Scribed by Tomasz M. Sobow; Marcin Maczkiewicz; Iwona Kloszewska


Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
38 KB
Volume
16
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

โœฆ Synopsis


Beeching, 1991)

, sometimes transferring their own disquietude at such discussions with relatives on to the reluctance of relatives to talk about DNR issues.

Perhaps, in the UK, we need to learn from many of our American colleagues who see it appropriate to formulate an advance directive that combines the living will with their equivalent of an Enduring Power of Attorney, early on in the illness before competence is well and truly lost (Prost and Whitehouse, 1995).

For the protection of staff and patients, it is as essential to develop DNR policies in psychiatric units as it is in any other health care setting (Cournos, 1986ยฑ87). Therefore a policy should be instituted in Old Age Psychiatry enabling well documented resuscitation/DNR decisions to become routine and form an integral part of each patient's care plan (Cournos, 1986ยฑ87;Prost and Whitehouse, 1995;Skerritt and Pitt, 1997).

By understanding patients' and family members' preferences for `end-of-life' care and treating them accordingly, we respectfully preserve their human dignity.


๐Ÿ“œ SIMILAR VOLUMES


Efficacy and safety of tianeptine in the
โœ H. Lรดo; J. Saiz-Ruiz; J. A. Costa e Silva; M. Ansseau; R. Herrington; A. Vaz-Ser ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 137 KB ๐Ÿ‘ 2 views

Depression is treated by a great variety of antidepressant treatments. SSRIs (such as fluoxetine) are well known: it is, however, sure that further progress is needed and the search for antidepressants with other mechanisms of action (such as tianeptine) or different efficacy is still of interest. A

Patient predictors of response to treatm
โœ Martin Steinberg; Cynthia A. Munro; Quincy Samus; Peter V.Rabins; Jason Brandt; ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 70 KB ๐Ÿ‘ 2 views

## Abstract ## Objective To investigate patient predictors of response to treatment of Major Depressive Episode (MDE) in Alzheimer's disease (AD). ## Methods Fortyโ€four outpatients with AD and MDE were randomized to receive either sertraline or placebo in a 12โ€week placeboโ€controlled, flexibleโ€d

Advances in the drug treatment of Alzhei
โœ B. E. Leonard ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 133 KB ๐Ÿ‘ 2 views

There are two main approaches to the treatment of Alzheimer's disease. The ยฎrst approach is to prevent the neurodegenerative changes that ultimately cause irreversible damage to the brain. As the excessive formation of betaamyloid protein appears to play a primary role in the neurodegenerative proce

SELEGILINE IN THE TREATMENT OF BEHAVIOUR
โœ BRIAN A. LAWLOR; PAUL S. AISEN; CYNTHIA GREEN; ELIZABETH FINE; JAMES SCHMEIDLER ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 97 KB ๐Ÿ‘ 2 views

Objective. The purpose of this study was to examine the behavioural and cognitive eects of selegiline in a group of moderately behaviourally disturbed AD patients. Design. This was a 14-week randomized double-blind placebo-controlled study of selegiline (10 mg) and placebo. Setting. An outpatient